Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Size (2025-2030)

The Digital Therapeutics for Cardiovascular Diseases (CVDs) Market was valued at $1.3 billion and is projected to reach a market size of $5.54 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 33.6%

More people are buying healthcare tools and changing their lifestyles, like being more health-conscious and using digital solutions. This is driving the growth of cardiovascular digital therapies around the world. These software tools, such as mobile apps and online coaching, are essential for managing issues like high blood pressure and heart failure. When the COVID-19 pandemic hit in early 2020, it shook up how healthcare was delivered, leading to a greater need for remote care and virtual rehab programs. Both doctors and patients started leaning on digital options to keep track of health, stay on top of medication, and get personalized support while avoiding face-to-face visits. Even though there were some bumps in the road trying to get these digital tools widely accepted, investments kept flowing into digital therapies. This was fueled by proof that these solutions can lower major heart issues by 45%, cut readmission rates by 50%, and help control blood pressure better. After the pandemic, digital therapies became vital for managing chronic heart disease. They fit into existing healthcare setups using both prescribed and over-the-counter methods, taking advantage of cloud data, wearables, and tech aimed at changing habits. As regulators wrap up approval processes and expand payment options, these practical digital solutions are likely to change cardiovascular care for the better by making it more accessible and personalized.

Key Market Insights:

During the early days of COVID-19, remote monitoring really took off, growing by 154% as healthcare providers started using digital tools like wearables and telehealth to keep track of blood pressure, heart rate, and ECG data.

 Now, with AI and machine learning in play, cardiovascular platforms can assess risk in real time and offer personalized care. This helps catch cardiac issues early and tailor treatments, leading to over 25% growth in the cardiac AI monitoring market.

 More than 40% of digital therapy solutions come with personalized coaching or symptom-tracking apps. These use mobile health design ideas, such as reminders for medication and small nudges, to help patients stick to their plans.

 Most of the market (about 60%) now uses cloud-based systems, which allow for scalable platforms that blend electronic health records, wearables, and analytics. This improves workflows for clinicians and keeps patients engaged.

 Finally, strategic partnerships between digital therapy vendors and healthcare systems make up around 35% of new product launches, helping more people access cardiac rehabilitation and manage chronic diseases through outpatient, home care, and telemedicine.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Key Drivers:

More people are dealing with heart problems these days.

As heart disease, high blood pressure, diabetes, and an aging population rise, there's a growing need for remote care options that focus on individual needs. Digital tools like mobile apps, wearables, and telehealth are helping patients keep track of their health and receive personalized support, filling gaps in care. Research shows that this demand is a big reason why digital therapeutics are becoming popular, making it easier to manage long-term health issues and reducing the need for in-person visits, which ultimately helps patients feel better.

Techs like AI and wearables are making it easier to monitor health in real-time.

New gadgets and smart analytics allow us to keep an eye on things like heart rate, blood pressure, and even daily habits. These tools give instant feedback and personalized coaching, which helps patients stick to their health plans. For example, platforms that use sensors and AI have been really effective, proving how important technology is in expanding the use of digital therapeutics.

There's a big shift towards focusing on value in healthcare and keeping costs down.

Healthcare systems and insurance providers are starting to prefer models that prioritize outcomes. Digital therapeutics fit well into this new way of thinking, showing clear improvements such as fewer hospital stays, better follow-through on treatments, and lower readmission rates—all while cutting costs. As the focus on value-based care reshapes how healthcare is delivered, digital therapeutics are becoming a smart and patient-friendly choice compared to traditional methods.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Restraints and Challenges:

Challenges Facing the Digital Therapeutics Market for Heart Conditions.

Even though digital therapeutics offer a lot of hope in heart care, there are some real challenges along the way. First off, the rules and payment systems are all over the place, making it hard for developers and insurance companies to know what to do. This slows down how quickly products can hit the market and how easily people can get covered for them. Then there's the issue of keeping patient data private and secure. With strict laws like HIPAA and GDPR in place, companies need to invest a lot in cybersecurity, which can be both costly and complicated. Another big challenge is that many older or less tech-savvy heart patients, especially those with lower incomes, just aren't engaging with these digital solutions. Plus, having too many apps can confuse them. On top of that, there are problems with getting different techs to work together, mainly because of outdated electronic health record systems and various device needs. This makes it tough for doctors to have smooth workflows. Lastly, there's a need for solid evidence to show how effective these treatments are in the long run, along with unclear ways to make money from them. These issues make it hard for the sector to be seen as trustworthy and sustainable.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Opportunities:

Growth Opportunities in Digital Therapeutics for Heart Care.

 Digital therapies for heart diseases have a lot of potential right now. First off, many people have heart issues but don’t even know it, especially in places like India where around 42% of adults with high blood pressure are unaware of their condition. This creates a real need for easy-to-access digital solutions. Then, with advances in technology like AI, IoT, and wearables, we can now detect risks in real time and keep an eye on patients remotely, with these new systems showing accuracy like traditional methods. Lastly, partnerships between device makers and healthcare providers, along with FDA-approved AI tools like smart stethoscopes, are helping to get these solutions into regular use and make them easier to get reimbursed. Put together, these factors are helping to bridge gaps in healthcare, use cutting-edge technology, and encourage collaboration, making digital heart therapies more likely to reach a wider audience globally.

DIGITAL THERAPEUTICS FOR CARDIOVASCULAR DISEASES (CVDS) MARKET REPORT COVERAGE:

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation:

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Component / Product Type

• Devices / Hardware
• Software / Digital Platforms
• Services

Software-based digital therapies like AI apps and cloud platforms are growing quickly in healthcare. Providers and patients are using these tools to make workflows smoother, tailor treatments, and help with sticking to medication. With software taking up about 70-85% of revenue and projected to keep growing at around 32%, advancements in AI diagnostics and patient engagement are driving this trend.

 Despite the rise of software, physical devices like wearables and monitors still lead the market, making up 58-74% of total revenue. These devices are crucial for real-time patient monitoring and produce important health data that supports digital therapies. Sales in this area are set to hit $93 billion by 2032, showing how vital they are for heart health.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Application / Service Use Case

• Cardiac Monitoring & Diagnosis
• CVD Health Informatics
• Cardiac Rehabilitation Programs
• Preventive & Lifestyle Management
• Medication Adherence & Treatment Support

Cardiac monitoring is the fastest-growing area in digital health for heart diseases. This growth comes from the rise of AI wearables, portable ECGs, and remote monitoring tools. AI systems can accurately spot issues like atrial fibrillation, allowing for quick action before serious problems arise. The demand is increasing due to advances in wireless ECG tech and cloud analytics, making monitoring easier than ever.

 While cardiac monitoring is racing ahead, health informatics and rehab programs are still key players. Health informatics tools use EHR data and analytics to provide personalized treatment insights for doctors. On the other hand, home-based rehab apps have been shown to work just as well as in-person sessions, improving patient compliance and lowering hospital readmissions by about 25%. These solutions build the core of many digital heart care strategies.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Product / Solution Type

• Monotherapy vs. Combination Therapy
• Mobile Apps (mHealth)
• Software as Medical Device (SaMD)

Mobile apps are growing fast, but SaMD is still the revenue leader, making up over 70% of the market for digital therapeutic solutions. These software platforms are regulated and often get FDA or CE approval, working well with electronic health records and remote devices. They provide care, diagnostics, and support for healthcare systems, which helps them gain acceptance in institutions.

 While standalone apps and SaMD tools are on the rise, combination therapy—where digital tools work with medications—holds the biggest market share at about 68%. These hybrid methods use digital solutions to improve medication adherence and patient outcomes.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Deployment Mode 

• Cloud‑Based
• On‑Premises

On-premise deployments are growing fast, especially in healthcare where data security and regulations matter. Hospitals and clinics in strict data areas are choosing to keep their digital systems in-house to avoid cloud risks. This choice shows their desire for control over patient data and ensures better protection against breaches while fitting in with their current setups.

 Cloud-based systems still lead the market, holding about 67.7% share due to their scalability and cost benefits. They’re great for managing large amounts of cardiovascular data across devices, supporting remote monitoring, quick updates, and easy connections with electronic health records. This makes cloud solutions the go-to for many cardiovascular care providers.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By End‑User / Customer Segment

• Hospitals & Clinics / Healthcare Providers
• Home‑care / Patients / Consumers
• Payers, Employers, Ambulatory Centers

The home-care segment is growing fast, thanks to more people wanting to take charge of their health, the rise of smartphones and wearables, and a shift toward remote healthcare. By 2024, it grabbed 34.5% of the cardiovascular digital health market, leading the way in patient demand.

 Meanwhile, hospitals and clinics still hold a major share, making up over 50% of the market revenue for cardiovascular digital therapies. They lead clinical trials and integrate well into existing healthcare systems, allowing them to roll out solutions on a large scale.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Business / Revenue Model

• B2B
• Direct-to-consumer (DTC)
• Outcome‑/ Value‑Based
• Pharma Partnerships

The DTC model, where people directly use heart health apps and coaching services, is growing rapidly thanks to better awareness and easy access. With more folks using smartphones, many are choosing tools for medication reminders and lifestyle tracking. This approach often offers free options and low monthly fees, helping heart disease patients manage their care without the usual barriers.

 On the other hand, the B2B model is still the biggest player in cardiovascular digital health, with providers and pharmaceutical companies using these platforms widely. By teaming up with organizations, these solutions are included in employee benefits and integrated into healthcare systems. This model's strength comes from stable revenue and easy integration, making B2B essential in the market.

Digital Therapeutics for Cardiovascular Diseases (CVDs) Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America leads the digital therapeutics market for heart diseases, taking up 40% of it. This is thanks to a strong digital health scene, high chronic illness rates, and good reimbursement options. Europe comes next at 27%, helped by digital health rules, solid public healthcare, and the early use of software for medical devices. The Asia-Pacific area has 22%, with countries like Japan, India, and China quickly adopting AI and mobile health tools for preventing and managing heart diseases. Latin America makes up 6%, where digital platforms are becoming more popular as cardiovascular risks rise, and mobile access expands. Lastly, the Middle East and Africa hold 5%, with growth driven by better digital health systems and more investment in remote patient monitoring in busy cities.

COVID-19 Impact Analysis on the Digital Therapeutics for Cardiovascular Diseases (CVDs) Market:

The COVID-19 pandemic really sped up the use of digital tools in heart care. With hospitals overrun and lockdowns in place, healthcare providers started using things like remote patient monitoring, video consultations, and personalized software to keep track of patients. They relied on tools such as AI-powered ECG monitors, mobile blood pressure trackers, and virtual rehab programs, so patients could get heart care from home. Research from this time showed that using telemedicine helped cut down on hospital readmissions and improved how doctors managed vital signs for heart failure and post-heart attack patients through video calls and phone check-ins. Plus, relaxed rules and better insurance coverage made it easier to roll out these digital solutions quickly. As a result, remote monitoring devices and health apps became key in preventing and managing chronic illnesses. This shift not only kept care going during a tough time but also reinforced the role of digital tools in mainstream heart treatment, setting the stage for their long-term use in healthcare.

Trends/Developments:

In April 2024, the American Heart Association shared findings about research using apps, wearables, and AI in heart care. They highlighted various projects that rely on smartphone apps, text messages, wearables, and AI for spotting cardiovascular risks, diagnosing strokes, and helping with rehab. These studies showed improved communication between patients and doctors and better access to care for everyone.

In February 2024, Biofourmis bought PhysioWave, a company that focuses on digital treatments for heart health. This move boosted Biofourmis’s lineup of heart care solutions and showed that investors are confident in this area while also expanding their tech skills.

In January 2024, Lupin Digital Health teamed up with the American College of Cardiology to launch a new Digital Therapeutics Certificate for cardiologists. This program recognizes doctors who are using remote cardiac rehab and digital heart failure treatments, helping to build trust and interest in digital care. Also, the U.S. Centers for Medicare & Medicaid Services introduced three new codes for covering and analyzing digital therapy data. This big change aims to clear up regulatory and financial issues, encouraging developers to speed up their research and helping patients find effective software therapies.

Key Players:

1. Pear Therapeutics
2. Omada Health
3. Biofourmis
4. WellDoc
5. Lark Technologies
6. AliveCor
7. Eko Health
8. Propeller Health
9. Better Therapeutics
10. Click Therapeutics